Serial Number | 90780728 |
Word Mark | THERAPURE |
Filing Date | Thursday, June 17, 2021 |
Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
Status Date | Thursday, September 8, 2022 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | NOT AVAILABLE |
Pseudo Mark | THERA PURE |
Goods and Services | Providing services to others in the nature of manufacture of nucleic acids, and amidites, enzymes and nucleotides involved in their synthesis and modification and lipids, sterols and other compounds useful for delivery to cells, for scientific and medical research and for use in manufacture of therapeutics, and process development services |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Friday, September 3, 2021 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | THERMO FISHER SCIENTIFIC (MILWAUKEE) LLC |
Party Type | 10 - Original Applicant |
Legal Entity Type | 16 - Limited Liability Company |
Address | MILWAUKEE, WI 53202 |
Event Date | Event Description |
Thursday, September 8, 2022 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
Thursday, September 8, 2022 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
Thursday, September 8, 2022 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
Tuesday, February 22, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Tuesday, February 22, 2022 | NON-FINAL ACTION E-MAILED |
Tuesday, February 22, 2022 | NON-FINAL ACTION WRITTEN |
Wednesday, February 16, 2022 | ASSIGNED TO EXAMINER |
Friday, September 3, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Monday, June 21, 2021 | NEW APPLICATION ENTERED |